Please login to the form below

Not currently logged in
Email:
Password:

Alder Biopharmaceuticals

This page shows the latest Alder Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Novartis says migraine prevention drug clears phase III trial

Novartis says migraine prevention drug clears phase III trial

Novartis and Amgen are in a race withand Alder Biopharmaceuticals to bring the first CGRP-blocking drug to market.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics